IP Valuation for Organ Regeneration
Oxfirst supported this company by helping it set up mechanisms to aggregate patents and systematically assessed the value of the patents, so to determine if they were appealing to the aggregator and what an adequate royalty rate for them would be.
The instruments provided to this firm helped them differentiate between commercially appealing IP and IP it should better stay away from.
This was limited of course to one single area of organ regeneration. If you apply the same model to the other areas, this will certainly comprise a unique financial outlook for a new industry, organ repair and bioengineering. Perhaps you would consider publishing this in a peer-reviewed journal? Would likely help us with fundraising.